Partnerships

AgriTech
Bioprocessing
Pharmaceuticals
Proteomics
Synthetic Biology

Multiply Labs is revolutionizing cell therapy production with ai

Multiply Labs is revolutionizing cell therapy production with robotic systems and AI-driven digital twins.

Multiply Labs is revolutionizing cell therapy production with robotic systems and AI-driven digital twins, cutting costs by up to 70%, increasing throughput, and reducing contamination ri

The Biotech Times Editorial Team  · 
Medical Devices

IBA to install first gantry proton therapy centre in central Italy

IBA has signed a contract with Rome's IFO to deliver a Proteus ONE proton therapy system, bringing gantry-based treatment to central and southern
IBA has signed a contract with Rome's IFO to deliver a Proteus ONE proton therapy system, bringing gantry-based treatment to central and southern
The Biotech Times Editorial Team  · 
AgriTech
Synthetic Biology

Cibus and Crystal Crop partner to gene-edit India's mustard crop

The deal gives Crystal Crop exclusive India rights to Cibus gene-editing technology targeting higher mustard yields across 8.5 million hectares.
The deal gives Crystal Crop exclusive India rights to Cibus gene-editing technology targeting higher mustard yields across 8.5 million hectares.
The Biotech Times Editorial Team  · 
Pharmaceuticals
Biologics

Boehringer Ingelheim funds WHO Foundation obesity drive with $5m

The German pharma group will contribute $5 million over three years to strengthen obesity and metabolic health systems in resource-limited settings.
The German pharma group will contribute $5 million over three years to strengthen obesity and metabolic health systems in resource-limited settings.
The Biotech Times Editorial Team  · 
Medical Devices
Diagnostics
Pharmaceuticals
Cell & Gene Therapy
Biologics

Penn Medicine and IBA form Noventra Oncology Alliance JV

The joint venture will offer end-to-end advisory and operational support to health systems building or expanding proton therapy programmes worldwide.
The joint venture will offer end-to-end advisory and operational support to health systems building or expanding proton therapy programmes worldwide.
The Biotech Times Editorial Team  · 
Medical Devices

Kessler Foundation and UPnRIDE partner on upright mobility study

Kessler Foundation and UPnRIDE are studying real-world use of the FDA-cleared standing mobility platform among rehabilitation patients.
Kessler Foundation and UPnRIDE are studying real-world use of the FDA-cleared standing mobility platform among rehabilitation patients.
The Biotech Times Editorial Team  · 
Pharmaceuticals
Biologics

Addex regains global GABAB PAM rights after Indivior R&D pullback

Addex Therapeutics has reclaimed its full GABAB positive allosteric modulator portfolio from Indivior, citing the UK firm's R&D rationalisation ahead of a planned
Addex Therapeutics has reclaimed its full GABAB positive allosteric modulator portfolio from Indivior, citing the UK firm's R&D rationalisation ahead of a planned
The Biotech Times Editorial Team  · 
Pharmaceuticals
Regulatory Science

EC approves leriglitazone as first pharmacological cALD treatment

Neuraxpharm and Minoryx win EU marketing authorisation for NEZGLYAL, the first oral drug approved for cerebral adrenoleukodystrophy in young boys.
Neuraxpharm and Minoryx win EU marketing authorisation for NEZGLYAL, the first oral drug approved for cerebral adrenoleukodystrophy in young boys.
The Biotech Times Editorial Team  · 
Pharmaceuticals
Biologics

Satellos wins FDA IND clearance for forazapadin in FSHD

Satellos Bioscience has cleared an IND for its AAK1 inhibitor in a second muscle disease, backed by US$5m from the FSHD Canada Foundation.
Satellos Bioscience has cleared an IND for its AAK1 inhibitor in a second muscle disease, backed by US$5m from the FSHD Canada Foundation.
The Biotech Times Editorial Team  · 
Cell & Gene Therapy
Pharmaceuticals

Ligand commits up to $47m to back AvenCell's allogeneic CAR-T pipeline

Ligand Pharmaceuticals will fund AvenCell Therapeutics in tranches tied to clinical milestones, taking a royalty on all current and future pipeline assets.
Ligand Pharmaceuticals will fund AvenCell Therapeutics in tranches tied to clinical milestones, taking a royalty on all current and future pipeline assets.
The Biotech Times Editorial Team  · 
Pharmaceuticals

Nuvectis NXP200 wins Breakthrough Therapy Designation in China for HGG

China's CDE has granted Breakthrough Therapy Designation to NXP200, a brain-penetrant BRAF inhibitor, for recurrent BRAF V600-mutant high-grade glioma.
China's CDE has granted Breakthrough Therapy Designation to NXP200, a brain-penetrant BRAF inhibitor, for recurrent BRAF V600-mutant high-grade glioma.
The Biotech Times Editorial Team  · 
Medical Devices
Digital Health

Precision Neuroscience closes $250m Series D for BCI expansion

The New York BCI company raised an oversubscribed round co-led by Pershing Square, bringing total funding to $430m since its 2021 founding.
The New York BCI company raised an oversubscribed round co-led by Pershing Square, bringing total funding to $430m since its 2021 founding.
The Biotech Times Editorial Team  · 
Pharmaceuticals
Biologics

HUTCHMED takes savolitinib-osimertinib combo to ESMO 2026

Two positive Phase III NSCLC studies, SAFFRON and SANOVO, will feature as oral presentations at ESMO Congress 2026 in Madrid this October.
Two positive Phase III NSCLC studies, SAFFRON and SANOVO, will feature as oral presentations at ESMO Congress 2026 in Madrid this October.
The Biotech Times Editorial Team  · 
Biologics
Synthetic Biology
Cell & Gene Therapy

Scarlet Therapeutics wins $14m DARPA deal for smart red blood cells

The Bristol biotech will lead an international consortium to engineer red blood cells that sense and respond to physiological changes.
The Bristol biotech will lead an international consortium to engineer red blood cells that sense and respond to physiological changes.
The Biotech Times Editorial Team  · 
Pharmaceuticals
Biologics

Zealand Pharma starts Phase 3 ZUPREME programme for petrelintide

The Copenhagen biotech and Roche partner have initiated three placebo-controlled trials enrolling around 7,000 participants across obesity sub-populations.
The Copenhagen biotech and Roche partner have initiated three placebo-controlled trials enrolling around 7,000 participants across obesity sub-populations.
The Biotech Times Editorial Team  · 
Biologics
Bioprocessing
Regulatory Science

ATCC wins $99m DOW contract to manage military medical countermeasures

ATCC will lead lifecycle management of vaccines, biologics and drugs for the US military's RAPID programme under a 10-year, $99 million contract.
ATCC will lead lifecycle management of vaccines, biologics and drugs for the US military's RAPID programme under a 10-year, $99 million contract.
The Biotech Times Editorial Team  · 
Biologics
Bioinformatics

Envisagenics and Boehringer Ingelheim in $1bn RNA splicing deal

Envisagenics' AI-powered SpliceCore platform will supply tumour-specific targets to Boehringer across ADC, T-cell engager and multispecific antibody programmes.
Envisagenics' AI-powered SpliceCore platform will supply tumour-specific targets to Boehringer across ADC, T-cell engager and multispecific antibody programmes.
The Biotech Times Editorial Team  · 
Biologics
Pharmaceuticals

PDS Biotech's PDS0101 combo shows 39-month survival in HNSCC trial

VERSATILE-002 Phase 2 results, published in JAMA Oncology, showed 39.3 months median overall survival in HPV16-positive head and neck cancer, more than
VERSATILE-002 Phase 2 results, published in JAMA Oncology, showed 39.3 months median overall survival in HPV16-positive head and neck cancer, more than
The Biotech Times Editorial Team  · 
Digital Health

New Era Energy inks 20-year, 207 MW power deal with Vistra

New Era Energy & Digital has contracted firm power for Phase 1 of its Texas data centre, with Vistra supplying up to 207 MW from an
New Era Energy & Digital has contracted firm power for Phase 1 of its Texas data centre, with Vistra supplying up to 207 MW from an
The Biotech Times Editorial Team  · 
Pharmaceuticals
Biologics

NewAmsterdam and Menarini win EC approval for obicetrapib

The European Commission has approved obicetrapib as both a monotherapy and fixed-dose combination, marking the CETP inhibitor's first regulatory clearance worldwide.
The European Commission has approved obicetrapib as both a monotherapy and fixed-dose combination, marking the CETP inhibitor's first regulatory clearance worldwide.
The Biotech Times Editorial Team  · 
Subscribe to Partnerships